{"groups":[{"description":"Participants who received nilotinib during the consolidation phase and, if eligible, entered the treatment-free remission phase following nilotinib discontinuation.","id":"FG000","title":"Nilotinib Treatment and Treatment-Free Remission Cohort"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Patient/guardian decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"215"}],"comment":"NTCS Phase: Patients who satisfied all the inclusion and none of the exclusion criteria were to be enrolled into the consolidation phase where the patients were treated with nilotinib with the same dose as prior to study entry. Duration of the consolidation phase was 52 weeks or until a patient experienced unacceptable toxicity, disease progression, death, loss to follow-up, and/or treatment was discontinued at the discretion of the Investigator or due to withdrawal of consent.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"203"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"NOT COMPLETED"}],"title":"Nilotinib Treatment Consolidation Phase"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"18"}],"type":"Patient/guardian decision"},{"reasons":[{"groupId":"FG000","numSubjects":"98"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"190"}],"comment":"TFR Phase: The duration of the TFR phase was up to 528 weeks after the last patient entered the TFR phase. Patients stopped taking nilotinib on the day they entered this phase.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"65"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"125"}],"type":"NOT COMPLETED"}],"title":"Nilotinib Treatment-free Remission Phase"}],"preAssignmentDetails":"Informed consent was obtained from each participant in writing before screening and before any study specific procedure was performed.","recruitmentDetails":"Recruitment for the study comprised a total of 215 participants, who were enrolled at 132 clinical sites distributed across 19 different countries.."}